Nobuo Nagano

8PUBLICATIONS
3CO-AUTHORS
PharmacogenomicsToxicology (incl. clinical toxicology)Nutritional epidemiologyCell physiologyClinical pharmacy and pharmacy practice
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 28, 2026
Patient characteristics associated with the need for high doses of tenapanor hydrochloride in dialysis patients with hyperphosphatemia: A pooled analysis of three clinical trials.

|Jul 01, 2026
Tenapanor reduces phosphate binder pill burden among hemodialysis patients in a post hoc phase 3 analysis.

|Oct 31, 2025
Association between serum hepcidin-25 levels and hyporesponsiveness to erythropoiesis-stimulating agents in Japanese patients receiving hemodialysis: a cross-sectional study.

Ryo Fujikawa, Nobuo Nagano, Yuko Mitobe

|Aug 07, 2024
Comparison of serum alkaline phosphatase levels between two measurement methods in chronic hemodialysis patients in Japan: involvement of ABO blood group system and relationship with mortality risk.

Nobuo Nagano, Ayaka Tagahara, Takahito Shimada

|Aug 14, 2023
Association between phosphate binder pill burden and mortality risk in patients on maintenance hemodialysis: a single-center cohort study with 7-year follow-up of 513 patients.

Nobuo Nagano, Chie Zushida, Ayaka Tagahara

|Feb 09, 2022
Impact of phosphate binders on medication dosing frequency, timing, and number of prescribed pills in hemodialysis patients.

Nobuo Nagano, Takahiro Fukushima, Risa Shikata

Pageof 2

Frequent Collaborators

1 joint publications

Ryo Fujikawa

1 joint publications

Yuko Mitobe

1 joint publications

Shinji Asada